ImpediMed Taps Former Hologic Executive for Top Job

There’s a new face in ImpediMed’s corner office.

The company has named Erik Anderson as managing director and CEO, succeeding Dr. Parmjot Bains, as of April 7. Anderson joined the company’s Board of Directors in February.

Bains will continue in an advisory role through June 30 to support a smooth leadership transition.

“I am thrilled to welcome Erik Anderson to ImpediMed in the role of CEO and managing director. Erik will focus on driving adoption of the SOZO platform across ImpediMed’s growing portfolio of indications, deepening strategic partnerships, and leading the company toward sustainable profitability. I am grateful for Parmjot’s significant contribution to ImpediMed and wish her well in the future,” ImpediMed Board Chair Christine Emmanuel-Donnelly said.

Anderson’s appointment occurs as ImpediMed’s business gains momentum with its breast cancer-related lymphedema (BCRL) business. The board determined the next phase of growth requires a step change in commercial execution, particularly in the United States. Anderson’s appointment reflects a focus on accelerating revenue growth, expanding health system adoption, managing costs, and advancing the company toward cash flow break-even and long-term value creation.

Anderson brings to ImpediMed extensive commercial leadership experience in the U.S. medical technology sector. Most recently, he was president of the Breast and Skeletal Health Division at Hologic Inc., a global developer of breast cancer care solutions spanning detection, intervention, and surgery, with deep engagement across breast radiologists and surgeons in U.S. health systems. During his tenure at Hologic, Anderson led a large, multi-franchise commercial organization and grew one of the company’s largest business units—a $1.6-plus billion global franchise.

He also has deep expertise in healthcare delivery, including hospital sales, clinical adoption, and reimbursement, along with strong relationships across health systems and key stakeholders aligned with ImpediMed’s growth priorities in BCRL, body composition, and heart health.

Anderson’s experience makes him a good fit for leading ImpediMed’s next phase of growth and expanding sales and distribution across U.S. health systems.

“I’m excited to step into the CEO role at ImpediMed. This is a company with an important role to play in cancer survivorship, with real opportunity to build from there. My focus is on delivering for patients and the clinicians who care for them every day, while building long-term value for shareholders,” Anderson stated.

Over the past two years, ImpediMed has established the operational and commercial foundations for sustainable growth. Under Bains’ leadership, the company expanded its addressable market by launching two new clinical indications on the SOZO platform: body composition monitoring for weight management and fluid status monitoring for heart health. During this period, BCRL reimbursement coverage expanded to 93% of covered lives in the United States.

ImpediMed is a global medical technology company that designs and manufactures bioimpedance spectroscopy (BIS) devices, providing clinicians with real-time insights for personalized patient care. The company’s SOZO Digital Health Platform and L-Dex are the first and only U.S. Food and Drug Administration-cleared BIS technology that noninvasively measures fluid status and tissue composition for both healthy and unhealthy populations and the assessment and management of secondary lymphedema, with a focus on breast cancer-related lymphedema. The platform also supports structured cancer survivorship programs and medical weight management, including patients on GLP-1 therapies, by providing real-time, whole-body insights. ImpediMed is aiming to redefine how clinicians monitor and manage body fluid and tissue status across diverse care pathways.